Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -130.37% is 50% below its 5-year average of -87.04%, near the low end of its 5-year range (-168.36%–-35.63%).
1.57% below its 12-month average of -128.36%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -30.32%.
RETURN ON ASSETS (ROA)
-130.37%
RETURN ON ASSETS (ROA) AVG TTM
-128.36%
RETURN ON ASSETS (ROA) AVG 3Y
-112.34%
RETURN ON ASSETS (ROA) AVG 5Y
-87.04%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-1.57%
CURRENT VS 3Y AVG
-16.05%
CURRENT VS 5Y AVG
-49.78%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-304.37%
vs the sector median at left
Gain Therapeutics, Inc.
Market Cap
$72.30M
Return on Assets (ROA)
-130.37%
TTM Avg
-128.36%
3Y Avg
-112.34%
5Y Avg
-87.04%
Market Cap
$72.16M
Return on Assets (ROA)
-86.58%
TTM Avg
-89.71%
3Y Avg
-79.07%
5Y Avg
-70.23%
Market Cap
$71.89M
Return on Assets (ROA)
-99.89%
TTM Avg
-66.19%
3Y Avg
-52.51%
5Y Avg
-39.81%
Market Cap
$69.48M
Return on Assets (ROA)
13.99%
TTM Avg
-24.80%
3Y Avg
-18.57%
5Y Avg
-29.63%
Market Cap
$75.53M
Return on Assets (ROA)
-5.84%
TTM Avg
-3.07%
3Y Avg
-3.13%
5Y Avg
-9.45%
Market Cap
$75.81M
Return on Assets (ROA)
-55.32%
TTM Avg
-66.75%
3Y Avg
-58.76%
5Y Avg
-49.95%
Market Cap
$75.82M
Return on Assets (ROA)
-41.94%
TTM Avg
-38.20%
3Y Avg
-35.26%
5Y Avg
-28.99%
Market Cap
$68.40M
Return on Assets (ROA)
-160.34%
TTM Avg
-132.74%
3Y Avg
-130.12%
5Y Avg
-105.91%
Market Cap
$68.60M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $72.30M | -130.37% | -128.36% | -112.34% | -87.04% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.16M | -86.58% | -89.71% | -79.07% | -70.23% |
| MindWalk Holdings Corp. (HYFT)vs › | $71.89M | -99.89% | -66.19% | -52.51% | -39.81% |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.48M | 13.99% | -24.80% | -18.57% | -29.63% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.53M | -5.84% | -3.07% | -3.13% | -9.45% |
| Hyperfine, Inc. (HYPR)vs › | $75.81M | -55.32% | -66.75% | -58.76% | -49.95% |
| Pulmonx Corporation (LUNG)vs › | $75.82M | -41.94% | -38.20% | -35.26% | -28.99% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.40M | -160.34% | -132.74% | -130.12% | -105.91% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | 35.31% | -14.11% | -23.46% | -20.68% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $76.76M | -902.18% | -2200.93% | -2200.93% | -2200.93% |
ROA
-130.4%
ROE
-178.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -88.35% |
| 2024-12-31 | -168.36% |
| 2023-12-31 | -119.66% |
| 2022-12-31 | -72.99% |
| 2021-12-31 | -35.63% |
| 2020-12-31 | -37.25% |
| 2019-12-31 | -332.20% |
| 2018-12-31 | -136.21% |
